The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Gilead Sciences has agreed to acquire Immunomedics, a Morris Plains, New Jersey-based clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs), for $21 billion.
Immunomedics’ lead product is Trodelvy (sacituzumab...
Biogen has announced a $250-million, 20-year initiative to eliminate fossil fuels across its operations and collaborate with institutions to advance the science on the health and environmental impacts of climate change. The initiative’s funding...
The US Department of Health and Human Services (HHS) and the US Department of Defense (DoD) released two documents outlining the US government’s strategy to deliver COVID-19 vaccine doses once vaccines are proven effective and safe and are...
A roundup of news from Germany (Bayer, Recursion), India (Mylan), Spain (Grifols, Alkahest), and the US (Merck KGaA, Pfizer, NKMax America).
Germany
Bayer, Recursion in AI Drug-Discovery Pact; Bayer Takes $50-M StakeBayer and Recursion...
AstraZeneca reports that is has temporarily paused its clinical trials for its COVID-19 vaccine, AZD1222, to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in a Phase III trial in...
The chief executive officers (CEOs) of nine biopharmaceutical companies developing COVID-19 vaccines issued a safety pledge to show united commitment to uphold the integrity of the scientific process as they work toward potential global regulatory...
Takeda Pharmaceutical has agreed to divest a portfolio of select prescription pharmaceutical products to Cheplapharm, a specialty pharmaceutical company headquartered in Greifswald, Germany, for $562 million.
The portfolio to be divested is...
Bayer has completed its previously announced acquisition of KaNDy Therapeutics, a Stevenage, UK-based clinical-stage biopharmaceutical company, in a deal worth up to $875 million.
KaNDy’s lead product is T-814, an oral, non-hormonal, once-daily...
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from J&J, CureVac, CSL, Roche, LabCorp, Qiagen, Astellas, Celltrion, Sinovac, and others.
J&J Reports Results of COVID Vaccine in Preclinical Challenge...
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their COVID-19 vaccine candidate, with an option for a further 100...
Mylan has agreed to acquire the related intellectual property and commercialization rights of the European thrombosis business of Aspen Pharmacare Holdings Limited, a Durban, South Africa-based pharmaceutical company, for EUR 641.9 million ($759...
AbbVie and I-Mab, a clinical-stage biopharmaceutical company headquartered in Shanghai, have signed a broad, global collaboration agreement, in a deal worth up to $1.94 billion, for the development and commercialization of lemzoparlimab, an...
A roundup of news from the UK (Takeda, Engitix Therapeutics, Intract Pharma, Celltrion), and the US (Gilead Sciences, Jounce Therapeutics, Mylan, Biocon, and Ionis).
UK
Takeda, Engitix in $500-M Pact To Develop Anti-Fibrotic Therapies Engitix...
The European Commission has signed an agreement with AstraZeneca for the purchase of up to 400 million doses of AstraZeneca’s COVID-19 vaccine. Also, AstraZeneca signed supply pacts with AMRI and Oxford Biomedica and provided an update on the...
The US Food and Drug Administration (FDA) has issued guidance, Control of Nitrosamine Impurities in Human Drugs, for immediate implementation. The guidance recommends steps, including a comprehensive risk-assessment strategy and other actions...
